Our mission is to support high quality educational programs for US HCPs that will improve patient care.
We will evaluate professional medical education grant requests that are independent of commercial bias and non-promotional in nature. Professional medical education grants can be requested to support a variety of different activities, including live events, web-based education, and enduring materials.
We will accept grant requests for professional medical education programs from the following types of organizations:
Academic medical centers, medical universities
Hospitals, community health centers
Professional medical associations/societies
Accredited continuing medical education providers
Medical education companies
We will also evaluate grant requests in support of research fellowships and awards from academic medical centers, medical universities and professional medical associations/societies. Individual recipients of these fellowships/awards should not have already been selected and Novartis can have no role in the selection of the recipient. Further Novartis funds cannot be used towards the physical award (eg plaque, trophy, etc).
In order to be considered, a complete grant application package must be submitted via the online portal at least 60 calendar days prior to the event date. If the completed grant application package is not received at least 60 days prior to the event date, the grant request may be denied.
Grant submissions for post-congress reviews/highlights must be submitted at least 60 days prior to the start date of the medical congress.
Required documents for submitting a Professional Medical Education Grant request
Increase knowledge of the mechanisms of action and safety and efficacy of current and emerging biologic treatments for AOSD.
Increase knowledge of the optimal pathway of diagnosis for a patient presenting with possible AOSD.
Increase knowledge of the relationship between AOSD and SJIA; identify strategies for optimal coordination of care between pediatric and adult rheumatologists.
Increase knowledge of strategies to achieve disease control using proper dosing to ensure clinical response; evaluate the safety and efficacy of switching biological agents for the treatment of AOSD.
Increase knowledge of the disease-related risk factors associated with impaired QoL in the long-term management of patients with AOSD.
Age-Related Macular Degeneration
Increase knowledge of the pathophysiology and mechanisms underlying the progressive nature of age-related macular degeneration (AMD)
Increase knowledge of the mechanism of action, safety and efficacy of new and emerging treatments, and their ability to reduce treatment burden
Educate HCPs on communication to patients and caregivers regarding disease management and the need for compliance with treatment and follow-up
Increase knowledge of the role played by newer imaging technologies in optimizing patient care
Guidelines, Goals and Evidence-Based Medicine - Educate on the review and implementation of the updated guidelines on spirometry.
Screening/Diagnosis - Educate on the current approach to testing and diagnosis.
Treatment - Increase knowledge of current and emerging treatments in asthma.
Secondary Symptoms and Systems - Increase knowledge of secondary systems and comorbidities of asthma.
Educate on the MOA, risks, benefits and safety profiles of available and emerging agents for the treatment of AS and nr-AxSpA.
Increase knowledge on the difference between inflammatory and mechanical back pain by identifying the signs and symptoms of Axial Spondyloarthritis (AxSpA)–an umbrella term that includes Ankylosing Spondylitis [AS] and Non-Radiographic Axial Spondyloarthritis [nr-AxSpA] to facilitate screening and referral; and support early detection and prompt diagnosis and treatment.
Educate on the importance of timely diagnosis of AxSpA; implement strategies to diagnose AxSpA, including recognizing the distinct presentation of nr-axSpA.
Increase knowledge on the importance of timely treatment in order to mitigate inflammation, prevent structural damage and the associated impairments on function and QoL.
Educate on “what primary care needs to know” about AxSpA. Utilize strategies that improve coordination of care amongst rheumatologists, primary care providers, orthopedic physicians, and other specialties involved in managing the care of AS patients; understand the roles of clinicians and discuss best practices for referral.
Guidelines, Goals and Evidence-Based Medicine - Educate on the review and implementation of the updated guidelines on spirometry.
Screening/Diagnosis - Educate on the current approach to testing and diagnosis.
Treatment - Increase knowledge of current and emerging treatments in COPD.
Secondary Symptoms and Systems - Increase knowledge of secondary systems and comorbidities of COPD.
Pathogenesis - Educate on the mechanism of food allergy development.
Biomarkers and Disease Progression - Educate on biomarker-based diagnostics in food allergies as well as allergy development and anaphylaxis.
Screening, Diagnosis - Increase knowledge of diagnostic criteria for food allergies.
Treatment - Educate on current and emerging treatments in food allergies.
Guidelines, Goals and Evidence-Based Medicine - Educate on guidelines on food allergy prevention, diagnosis and management.
Clinical Trials - Increase knowledge of ongoing and published clinical trials in food allergy treatment and management.
Comprehensive Approach to Care - Increase knowledge of best practices in an integrated approach to care among allergists and other health care providers.
Quality of Life - Educate on the areas of diminished quality of life for food allergy patients and caregivers.
Increase knowledge of efficacy and safety of guideline directed medical therapies in order to address the progressive nature of heart failure
Increase knowledge of available treatments and clinical trial data in order to develop patient centric management plans for patients with heart failure with reduced ejection fraction or with preserved ejection fraction
Increase knowledge on how to recognize heart failure patients most at risk for hospital readmission and the burden of high readmission rates on patients, caregivers and healthcare systems
Increase knowledge of the impact of HF hospitalization as a trajectory change in patients with HF and a critical decision point for optimizing guideline directed medical therapy
Increase knowledge of the pathophysiology of long term exposure to elevated LDL-C levels and its impact as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD)
Increase knowledge of safety and efficacy of current and emerging lipid lowering treatments
Increase knowledge of the most recent cholesterol guidelines and the need for patients to reach recommended evidence-based LDL-C goals
Increase knowledge of the implementation of individualized patient-centered treatment plans for ASCVD patients with persistently elevated LDL-C levels
Increase knowledge on the role of Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease and the importance of Lp(a) screening as part of a comprehensive ASCVD management strategy
Educate on current diagnostic criteria for timely diagnosis of biomarker-based strategies to assess MS activity and treatment response.
Educate on how to identify patients for whom high-efficacy DMTs are appropriate; discuss the risks and benefits; provide strategies to lower any barriers to HET adoption.
Increase knowledge of the mechanisms of action of current and emerging immunotherapies, their relevance to treatment decisions, and the relative risks and benefits of immunotherapeutic options.
Educate on how to identify patients with pediatric-onset MS & patients in underserved populations; determine appropriate treatment; assess available data on approved disease-modifying therapies for treatment.
Increase knowledge of cognitive impairment and fatigue, recommend optimal screening, monitoring, and treatment strategies; address barriers to optimal management and increase clinician and patient awareness about the prevalence, impact, and appropriate management of cognitive symptoms.
Educate on treatment optimization approaches to balance cost with patient outcomes.
Educate on the MOA, outline the safety and efficacy of currently available and emerging biologic agents for the treatment of psoriasis.
Increase knowledge of the challenges that psoriasis presents across specialties, including Dermatology and Rheumatology.
Educate on the importance of tailoring treatment to control the key domains of psoriatic disease, a condition characterized by systemic inflammation.
Increase knowledge of the impact of psoriasis on patient reported outcomes (PROs) and quality of life.
Increase knowledge of the role of a multidisciplinary care team, using shared decision-making strategies, to guide treatment choices and measurable goals to improve patient outcomes.
Educate on the latest therapeutic developments for the treatment of psoriatic disease; describe the mechanisms, safety, and efficacy for available and emerging agents.
Educate on the progression of PsA from subclinical joint inflammation to pre-PsA to the diagnosis of PsA.
Increase knowledge of the benefits of timely referral and collaborative, multidisciplinary management of psoriatic disease patients; assess the evidence supporting treat-to-target strategies in inflammatory diseases, specifically PsA.
Educate on the six domains of psoriatic disease; tailor treatment to control the key domains of psoriatic disease, a condition characterized by systemic inflammation.
Educate on strategies for assessing and monitoring disease activity and response to therapy; differentiate the disease measures of PsA from other rheumatic diseases (i.e., rheumatoid arthritis).
Rare Glomerular Kidney Disease
Pathogenesis - Educate on the role of pathogenesis in rare glomerular kidney disease
Treatment - Increase knowledge of current and emerging treatments for rare glomerular kidney disease
Screening/Diagnosis - Educate on the current approach to testing and diagnosis of rare glomerular kidney disease
Clinical Trials - Increase knowledge of ongoing and published clinical trials in rare glomerular kidney disease
Coordination of Care - Educate on best practices in an integrated approach to care among nephrologists and other health care providers.
Pathogenesis - Educate on the theoretical development of Sjogren’s syndrome.
Biomarkers and Disease Progressio - Increase knowledge of the utility of biomarkers in diagnosis and patient classification.
Screening and Diagnosis - Increase knowledge of the diagnostic criteria for Sjogren’s syndrome.
Guidelines, Goals and Evidence-Based Medicine - Increase knowledge of the diagnostic criteria and guidelines on management of Sjogren’s syndrome.
Comprehensive Approach - Increase knowledge of best practices in an integrated approach to care among specialists and other health care providers.
Quality of Life - Educate on the areas of diminished quality of life for patients.
Increase knowledge of recent advances in medical treatment options for renal transplantation.
Increase knowledge of the risks and benefits of existing and emerging/novel immunosuppressive therapy regimens in solid organ transplantation.
Educate on the value of assessing short-term and long-term outcomes in renal transplantation.
Increase knowledge of how the iBox Score predicts kidney allograft survival and response to treatment of individual patients.
Educate on how to identify solutions for patient adherence to medication after kidney transplantation.
Educate on the sequencing of therapies and the treatment recommendations for combination therapy for HR+/HER2- in pre- and post-menopausal patients with neoadjuvant, adjuvant or advanced breast cancer
Educate on the relevance and importance of next generation sequencing, molecular testing, testing in tumor vs blood in metastatic HR+/HER2- breast cancer
Educate on adverse event management strategies to ensure optimal patient outcomes and adherence with the use of treatments for metastatic HR+/HER2- breast Cancer
Chronic Myeloid Leukemia (CML)
Educate on the current and emerging treatment landscape in third line CML
Educate on the sequencing of treatments
Educate on the unmet medical needs (resistant mutations such as T315I) in CML patients in later lines of treatment
Educate on the MOA of CML treatments
Educate on the healthcare resource utilization (HCRU) in CML patients in later lines of treatment
Educate on the clinical benefits of molecular monitoring/mutation testing, treatment milestones per NCCN guidelines and deep molecular response (DMR)/ Treatment free remission (TFR) for patients with CML
Educate on how to manage adverse events, dose optimization and adherence to treatments to ensure optimal patient outcomes
Gastrointestinal Cancers (GI)
Educate on the impact of treatment-related toxicities (i.e. adverse effects) among patients undergoing therapy for gastrointestinal cancers and their management
Educate on cancer recurrence risk and ability to identify relapse early in esophageal, gastric, pancreatic, and colorectal cancers
Educate on treatment modalities and sequencing of therapies (immuno-oncologic agents, targeted therapies, combination therapies)
Educate on mechanisms of disease in gastrointestinal cancers and future therapeutic options
Educate on best practices to inform clinical decisions and testing methodologies
Immune Thrombocytopenic Purpura (ITP)
Educate on the current and emerging treatment landscape in first line and second line settings of immune thrombocytopenia
Educate on long term management strategies with persistent/chronic ITP to endure optimal patient outcomes and adherence
Educate on the various pathways in treating ITP
Melanoma and BRAF Therapies in Melanoma
Educate on the rationale for combination immunotherapies, targeted therapies and novel or emerging therapies for Melanoma
Educate on optimal sequencing of immunotherapies and targeted therapies
Educate on the relevance and timely need for BRAF testing in the early and advanced setting
Educate on AE management strategies to ensure optimal patient outcomes and adherence
Educate on the current and emerging treatment landscape in higher risk MDS (Int., High and V. high) and AML
Educate on the involvement of the TIM3 pathway in higher risk MDS
Educate on emerging role of Immune dysregulation in MDS and role of Immuno-myeloid therapy
Educate on the burden of disease, diagnosis and management complications, and importance of biomarker testing in higher risk MDS
Educate on adverse event management strategies with MDS therapies to ensure optimal patient outcomes and adherence
Neuroendocrine Tumors (NETs)
Recognize the challenges with the accurate diagnosis and management of NETs/Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Understand the impact of NETs/GEP-NETs on patient quality of life (QOL)
Understand evolving data regarding diagnosis and imaging modalities for NETs/GEP-NETs
Recognize the importance of early intervention upon clinical or radiological progression of NETs/GEP-NETs
Explain the importance of appropriate treatment sequencing and selection for NETs/GEP-NETs
Discuss the current and emerging treatment landscape for NETs/GEP-NETs
Consider the appropriate patient type and tumor origin/characteristics when determining individual treatment selections
Consider the use of guidelines for the diagnosis and treatment of NETs/GEP-NETs
Apply a multidisciplinary approach to the management of NETs/GEP-NETs
Non-Small Cell Lung Cancer (NSCLC)
Educate on the clinical value of up-front, multi-modal diagnostic testing to improve outcomes in patients with NSCLC using targeted therapies as first line therapy
Educate on optimal testing methodologies (tissue and liquid biopsy) to identify actionable oncogenic drivers in metastatic NSCLC (including METex14 mutations)
Educate on the importance of METex14 as an oncogenic driver associated with poor prognosis in NSCLC
Educate on the role of pro-tumor inflammation (PTI) inhibition in Lung cancer and strong understanding of MOA and the potential role of IL-1 β
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Educate on current and emerging treatment landscape of PNH, including targeting the proximal complement pathways
Educate on adverse event management strategies with PNH therapies to ensure optimal patient outcomes and adherence
PIK3CA-Related Overgrowth Spectrum (PROS)
Recognize barriers to optimal care due to lack of awareness of PROS, PROS terminology and the various disorders that fall under within this umbrella term
Discuss challenges in PROS diagnosis, including phenotypic variability of these disorders, the impact of diagnostic delay/disease burden, and/or challenges with genetic testing
Consider the patient’s perspective, quality of life and burden of disease when formulating a treatment plan for PROS
Recognize treatment options for PROS and the importance of treating the underlying disease as well as the symptoms
Discuss barriers to optimal care due to lack of awareness of PROS Guidelines
Recognize the role of a multi-disciplinary team and need for a collaborative approach in the diagnosis and treatment of PROS
Discuss the role of prostate-specific membrane antigen (PSMA) as a diagnostic and prognostic Biomarker for Prostate Cancer
Discuss the utility and appropriate use of novel imaging modalities including interpretation of the imaging results for advanced PC
Understand the mechanism of action (MOA) of radioligand therapy (RLT) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Differentiate current and evolving PC treatments (ex. systemic vs targeted) for mCRPC
Understand the current and emerging treatment landscape in mCRPC
Explain the importance of appropriate treatment sequencing and selection for treatment of mCRPC
Consider patient types that are most appropriate for current and emerging mCRPC treatments
Utilize a multi-disciplinary team and collaborative approach for the diagnosis and treatment of mCRPC
Consider the patient’s perspective and quality of life when formulating a treatment plan for Prostate Cancer
Recognize barriers to optimal care for diverse and minority populations due to lack of awareness of Prostate Cancer disease incidence, burden and diversity in clinical trials.
Sickle Cell Disease (SCD)
Address gaps in scientific knowledge among SCD experts and general practitioners treating SCD patients on the burden of disease specifically vaso-occlusion mediated end organ damage in adult and pediatric populations
Educate on the current and emerging treatment landscape in SCD
Increase understanding of the mechanism of disease and the different types of SCD therapies in vaso-occlusive crises, how to use combination treatments to facilitate adherence, and the economic value in the treatment of patients
Increase awareness of the sickle cell pain crisis pathophysiology, diagnosis, management and chronic implications (i.e. end organ damage) for the ER and community
Educate on how to implement multidisciplinary collaborations to improve care for SCD patients
Educate on the effective means of reducing and preventing vaso-occlusive crises in SCD patients in the ER and community setting
Educate on the clinical management of COVID-19 and SCD patients
T-Cell Therapies in B-Cell Malignancies
Educate the medical community the current and emerging treatment landscape of T-Cell therapies in the treatment of B-Cell malignancies, including r/r DLBCL and FL, and pALL
Educate community HCPs on the value of CAR-T therapy and the importance of timely referral and broad access to treatment for patients in need
Educate community HCPs on differentiation of T-Cell therapies, appropriate patient selection/eligibility, and optimal management of patients undergoing CAR-T therapy
Novartis considers funding for established fellowship programs with non-profit organizations including medical societies, academic institutions and organizations that align with the Novartis mission of addressing identified education gaps in particular therapeutic areas of interest currently listed online.
Requirements for seeking fellowship funding
Fellowships must have established both eligibility and selection criteria for fellows and an independent committee for fellowship selection. Fellows cannot have been selected at the time support is sought. To seek funding support, the following documents must be submitted:
Program objectives or specified research priorities
Program agenda or timeline
Letter of request and outcomes measurement/evaluation plan
The fellowship term may be for up to 1 year. Organizations can apply for the additional years if needed. Novartis funding cannot go towards any overhead including admin expenses, insurance, lodging, etc.
Funding requests that will not be supported
• Requests received less than 60 days prior to the activity start date • Requests that are not within the identified therapeutic areas of interest • Requests for textbooks or equipment-related requests only • Recognition awards • Requests for meals only • Requests for travel or conference registration fees only
Please do not consider any request approved until you have received written documentation from Novartis that your application has been approved for funding and all of the required paperwork, including a counter-signed original Letter of Agreement, has been received by you. Any expenses incurred prior to receiving written support of the program by Novartis are taken at your own risk.
Previous support by Novartis does NOT guarantee future support as each request is evaluated on individual merit. If you have any questions, please contact a member of the US Professional Medical Education or Patient Advocacy Teams. Please do NOT contact your sales representative, medical science liaison, regional scientific director, or marketing personnel regarding the status of a request.
Novartis will review each submission in a timely manner. Your prompt response to requests for any additional information is critical to this process and appreciated.
Novartis is aware of the growing need for education and support for the medical and patient/caregiver communities. Many more requests are received than can be funded and we regret that we cannot accommodate every request. However, your submission will receive a fair and thorough review. In return, please take time to consider how your program fits within the therapeutic areas of interest for Novartis and the established regulations, laws and guidelines before submitting a request.